Current guidelines (ADA-2023, KIDGO-2022, and ESC-2023) recommend SGLT-2 inhibitors and GLP-1 receptor agonists as first-line therapies in type 2 diabetes patients with cardiovascular disease, chronic kidney disease, and heart failure. The gene discussed is GLP1R; the disease is chronic kidney disease.